Audentes Therapeutics, Inc. BOLD is a biotechnology company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing ...

Japanese pharma Astellas and its new biotech buyout Audentes got a Christmas gift from the FDA when the agency lifted a clinical hold on its gene therapy. It’s been a tough 12 months for Audentes.

Audentes Therapeutics, Inc., a biotechnology company committed to the development and commercialization of gene therapy products for patients with serious, rare diseases, today announced the closing ...

The clinical trial of a gene therapy for a rare inherited disease that causes muscle weakness has been put on hold following the deaths of two patients. Last week, Audentes Therapeutics – which ...

Audentes Therapeutics Inc. (NASDAQ: BOLD) shares more than doubled on Tuesday after the firm announced that it would be acquired by Astellas. Although Audentes has only been public for just over three ...

Audentes Therapeutics (BOLD) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which ...

Audentes Therapeutics Inc. (NASDAQ: BOLD) saw its shares drop early on Wednesday after the company announced the pricing of its secondary offering. The company said that it intends to price its 5.2 ...

SAN FRANCISCO--(BUSINESS WIRE)--Audentes Therapeutics, Inc., an Astellas company, today announced that a third study patient has passed away in the ASPIRO clinical trial evaluating AT132 in patients ...

TOKYO and SAN FRANCISCO, Jan. 15, 2020 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503) (President and Chief Executive Officer: Kenji Yasukawa, Ph.D., "Astellas") today announced that it has ...

Two patients in a study of a high-dose gene therapy for a rare muscle disorder have died, heightening worries about the safety of potent treatments under development for other diseases. Audentes ...